Epidermal growth factor receptor imaging in human head and neck cancer xenografts

References

• Rojas A, Vojnovic B, Johns H, Joiner MC, Martindale C, Fowler JF, et al. Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: Therapeutic gain comparisons for fractionated x-ray schedules. Radiother Oncol 1996;39:53–64.
   PubMed Web of Science ®Google Scholar
• Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study DAHANCA) Protocol 5-85. Radiother Oncol 1998;46: 135–46.
   Google Scholar
• Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: Results of a phase III randomized trial. J Clin Oncol 2012;30: 1777–83.
   PubMed Web of Science ®Google Scholar
• Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6:701–8.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354: 567–78.
   PubMed Web of Science ®Google Scholar
• Stegeman H1, Rademakers SE, Span PN, Takes RP, van der Kogel AJ, Kaanders JH, et al. Hypoxia, metabolism, and growth factor signaling in head and neck squamous cell carcinoma: Correlation between primary and xenograft tumors. Head Neck 2014;36:1288–95.
   PubMed Web of Science ®Google Scholar
• Bussink J, van Herpen CM, Kaanders JH, Oyen WJ. PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol 2010;11:661–9.
   PubMed Web of Science ®Google Scholar
• Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials 2013;34:8690–707.
   PubMed Web of Science ®Google Scholar
• Stegeman H, Kaanders JH, van der Kogel AJ, Iida M, Wheeler DL, Span PN, et al. Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models. Radiother Oncol 2013;106:383–9.
   PubMed Web of Science ®Google Scholar
• Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008;9:288–96.
   PubMed Web of Science ®Google Scholar
• van Dijk LK, Boerman OC, Kaanders JH, Bussink J. PET imaging in head and neck cancer patients to monitor treatment response: A future role for EGFR-targeted imaging. Clin Cancer Res Epub 2015 Apr 30. pii: clincanres.0348.2015.
   Google Scholar
• Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmaco Sci 2008;29:57–61.
   PubMed Web of Science ®Google Scholar
• Jain RK. Transport of molecules, particles, and cells in solid tumors. Ann Rev Biomed Eng 1999;1:241–63.
   PubMed Web of Science ®Google Scholar
• Sihver W, Pietzsch J, Krause M, Baumann M, Steinbach J, Pietzsch HJ. Radiolabeled cetuximab conjugates for EGFR targeted cancer diagnostics and therapy. Pharmaceuticals Basel) 2014;7:311–38.
   Google Scholar
• Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, et al.89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90)Y and 177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005;46:1898–906.
   PubMed Web of Science ®Google Scholar
• Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007;34: 850–8.
   PubMed Web of Science ®Google Scholar
• Hoeben BA, Molkenboer-Kuenen JD, Oyen WJ, Peeters WJ, Kaanders JH, Bussink J, et al. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model. Int J Cancer 2011;129:870–8.
   PubMed Web of Science ®Google Scholar
• van Dijk LK, Hoeben BA, Kaanders JH, Franssen GM, Boerman OC, Bussink J. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F (ab’)2. J Nucl Med 2013;54:2118–24.
   PubMed Web of Science ®Google Scholar
• Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Letters 2010;584:2670–80.
   PubMed Web of Science ®Google Scholar
• Wu AM. Engineered antibodies for molecular imaging of cancer. Methods 2014;65:139–47.
   PubMed Web of Science ®Google Scholar
• van Dijk LK, Hoeben BA, Stegeman H, Kaanders JH, Franssen GM, Boerman OC, et al. 111In-cetuximab-F (ab’)2 SPECT imaging for quantification of accessible epidermal growth factor receptors EGFR) in HNSCC xenografts. Radiother Oncol 2013;108:484–8.
   PubMed Web of Science ®Google Scholar
• Gainkam LO, Caveliers V, Devoogdt N, Vanhove C, Xavier C, Boerman O, et al. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging 2011;6:85–92.
   PubMed Web of Science ®Google Scholar
• Garkavij M, Samarzija M, Ewers SB, Jakopovic M, Tezak S, Tennvall J. Concurrent radiotherapy and tumor targeting with 111In-HMFG1-F (ab’)2 in patients with MUC1- positive non-small cell lung cancer. Anticancer Res 2005;25: 4663–71.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Yoo TM, Kim IS, Kim MK, Le N, Webber KO, et al. L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. Cancer Res 1996;56:3788–95.
   PubMed Web of Science ®Google Scholar
• Kareem H, Sandstrom K, Elia R, Gedda L, Anniko M, Lundqvist H, et al. Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF. Tumour Biol 2010;31:79–87.
   PubMed Web of Science ®Google Scholar
• Bei R, Budillon A, Masuelli L, Cereda V, Vitolo D, Di Gennaro E, et al. Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol 2004;204:317–25.
   PubMed Web of Science ®Google Scholar
• Bei R, Pompa G, Vitolo D, Moriconi E, Ciocci L, Quaranta M, et al. Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J Pathol 2001;195:343–8.
   PubMed Web of Science ®Google Scholar
• Mehra R, Serebriiskii IG, Dunbrack RL, Jr., Robinson MK, Burtness B, Golemis EA. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat 2011;14:260–79.
   PubMed Web of Science ®Google Scholar
• Riesterer O, Yang Q, Raju U, Torres M, Molkentine D, Patel N, et al. Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers. Int J Radiat Oncol Biol Phys 2011;79:1179–87.
   PubMed Web of Science ®Google Scholar
• Yamatodani T, Ekblad L, Kjellen E, Johnsson A, Mineta H, Wennerberg J. Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Research Clin Oncol 2009; 135:395–402.
   PubMed Web of Science ®Google Scholar
• Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316–26.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Okamoto I, Okabe T, Iwasa T, Satoh T, Nishio K, et al. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer 2008;122:1530–8.
   PubMed Web of Science ®Google Scholar
• Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Differentiation 2002;13:355–62.
   Web of Science ®Google Scholar
• Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, et al. Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta 2014;1845:136–54.
   PubMed Web of Science ®Google Scholar
• Histed SN, Lindenberg ML, Mena E, Turkbey B, Choyke PL, Kurdziel KA. Review of functional/anatomical imaging in oncology. Nuc Med Commun 2012;33:349–61.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hong H, Cai W. PET tracers based on Zirconium-89. Curr Radiopharm 2011;4:131–9.
   PubMedGoogle Scholar
• Van Dijk LK, Yim C-B, Boerman OC, Franssen GM, Kaanders JHAM, Rajander J, Solin O, Gronroos TJ, Bussink J .PET of EGFR with 64Cu-cetuximab-F(ab’)2 in mice with head and neck squamous cell carcinoma xenografts In: Contrast Media and Molecular Imaging. DOI: 10.1002/cmmi.1659..
   Google Scholar
• van Dijk LK, Boerman OC, Franssen GM, Lok J, Kaanders JH, Bussink J. Early response monitoring with 18F-FDG PET and cetuximab-F (ab’)2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model. J Nucl Med 2014;55: 1665–70.
   PubMed Web of Science ®Google Scholar
• Wattenberg MM, Kwilas AR, Gameiro SR, Dicker AP, Hodge JW. Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets. Br J Cancer 2014;110:1472–80.
   PubMed Web of Science ®Google Scholar
• van Dijk LK, Boerman OC, Franssen GM, Kaanders JH, Bussink J. 111In-cetuximab-F (ab’)2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model. J Nucl Med 2015;56: 287–92.
   PubMed Web of Science ®Google Scholar
• Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, et al. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer 2013;13:84.
   PubMed Web of Science ®Google Scholar
• Mesía R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck CONCERT-1): A randomised, controlled, open-label phase 2 trial. Lancet Oncol 2015;16:208–20.
   PubMed Web of Science ®Google Scholar
• Poulin-Costello M, Azoulay L, Van Cutsem E, Peeters M, Siena S, Wolf M. An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial 20020408) in patients with chemotherapy refractory metastatic colorectal cancer. Targeted Oncol 2013;8:127–36.
   PubMed Web of Science ®Google Scholar
• Voigt M, Braig F, Gothel M, Schulte A, Lamszus K, Bokemeyer C, et al. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia 2012;14:1023–151.
   PubMed Web of Science ®Google Scholar
• Baselga J, Swain SM. Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463–75.
   PubMed Web of Science ®Google Scholar